Your browser doesn't support javascript.
loading
Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma.
Christgen, Matthias; Kandt, Leonie Donata; Antonopoulos, Wiebke; Bartels, Stephan; Van Bockstal, Mieke R; Bredt, Martin; Brito, Maria Jose; Christgen, Henriette; Colpaert, Cecile; Cserni, Bálint; Cserni, Gábor; Daemmrich, Maximilian E; Danebrock, Raihanatou; Dedeurwaerdere, Franceska; van Deurzen, Carolien Hm; Erber, Ramona; Fathke, Christine; Feist, Henning; Fiche, Maryse; Gonzalez, Claudia Aura; Ter Hoeve, Natalie D; Kooreman, Loes; Krech, Till; Kristiansen, Glen; Kulka, Janina; Laenger, Florian; Lafos, Marcel; Lehmann, Ulrich; Martin-Martinez, Maria Dolores; Mueller, Sophie; Pelz, Enrico; Raap, Mieke; Ravarino, Alberto; Reineke-Plaass, Tanja; Schaumann, Nora; Schelfhout, Anne-Marie; De Schepper, Maxim; Schlue, Jerome; Van de Vijver, Koen; Waelput, Wim; Wellmann, Axel; Graeser, Monika; Gluz, Oleg; Kuemmel, Sherko; Nitz, Ulrike; Harbeck, Nadia; Desmedt, Christine; Floris, Giuseppe; Derksen, Patrick Wb; van Diest, Paul J.
Affiliation
  • Christgen M; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Kandt LD; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Antonopoulos W; Institute of Pathology, University Clinics Heidelberg, Heidelberg, Germany.
  • Bartels S; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Van Bockstal MR; Department of Pathology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Bredt M; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Brito MJ; Pathology and Breast Unit, Champalimaud Foundation, Lisbon, Portugal.
  • Christgen H; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Colpaert C; Department of Pathology, Universitair Ziekenhuis Leuven, Leuven, Belgium.
  • Cserni B; TNG Technology Consulting GmbH, Budapest, Hungary.
  • Cserni G; Department of Pathology, University of Szeged, Szeged, Hungary.
  • Daemmrich ME; Group Practice for Pathology Schweinfurt, Schweinfurt, Germany.
  • Danebrock R; Institute of Pathology, Johannes Wesling Clinics Minden, Minden, Germany.
  • Dedeurwaerdere F; Laboratorium voor pathologie, AZ Delta, Roeselare, Belgium.
  • van Deurzen CH; Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Erber R; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), and Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
  • Fathke C; Institute of Pathology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
  • Feist H; Institute of Pathology, Diakonissenkrankenhaus Flensburg, Flensburg, Germany.
  • Fiche M; Institute of Pathology Aurigen, Aurigen SA, Lausanne, Switzerland.
  • Gonzalez CA; Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
  • Ter Hoeve ND; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Kooreman L; Institute of Pathology and GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Krech T; Institute of Pathology, University Clinics Hamburg-Eppendorf, Hamburg, Germany.
  • Kristiansen G; Germany and Pathocom Network for Pathology, Osnabrück, Germany.
  • Kulka J; Institute of Pathology, University Hospital Bonn, Bonn, Germany.
  • Laenger F; 2nd Department of Pathology, Semmelweis University Budapest, Budapest, Hungary.
  • Lafos M; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Lehmann U; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Martin-Martinez MD; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Mueller S; Institut de Pathologie et Genetique Gosselies, Gosselies, Belgium.
  • Pelz E; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Raap M; Institute of Pathology Viersen, Viersen, Germany.
  • Ravarino A; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Reineke-Plaass T; Institute of Pathology, University of Cagliari, Cagliari, Italy.
  • Schaumann N; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Schelfhout AM; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • De Schepper M; Department of Pathology, OLV Ziekenhuis Aalst, Aalst, Belgium.
  • Schlue J; Department of Pathology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium.
  • Van de Vijver K; Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
  • Waelput W; Institute of Pathology, Hannover Medical School, Hannover, Germany.
  • Wellmann A; Cancer Research Institute Ghent, Ghent University Hospital, Ghent, Belgium.
  • Graeser M; Department of Pathology, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
  • Gluz O; Institute of Pathology Celle, Celle, Germany.
  • Kuemmel S; West German Study Group, Moenchengladbach, Germany.
  • Nitz U; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany.
  • Harbeck N; Gynecologic University Clinic Hamburg-Eppendorf (UKE), Hamburg, Germany.
  • Desmedt C; West German Study Group, Moenchengladbach, Germany.
  • Floris G; Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany.
  • Derksen PW; West German Study Group, Moenchengladbach, Germany.
  • van Diest PJ; Breast Unit, Kliniken Essen-Mitte, Essen, Germany, and Charité - Universitätsmedizin Berlin, Department of Gynecology with Breast Center, Berlin, Germany.
J Pathol Clin Res ; 8(2): 191-205, 2022 03.
Article in En | MEDLINE | ID: mdl-34889530
ABSTRACT
Invasive lobular breast carcinoma (ILC) is the second most common breast carcinoma (BC) subtype and is mainly driven by loss of E-cadherin expression. Correct classification of BC as ILC is important for patient treatment. This study assessed the degree of agreement among pathologists for the diagnosis of ILC. Two sets of hormone receptor (HR)-positive/HER2-negative BCs were independently reviewed by participating pathologists. In set A (61 cases), participants were provided with hematoxylin/eosin (HE)-stained sections. In set B (62 cases), participants were provided with HE-stained sections and E-cadherin immunohistochemistry (IHC). Tumor characteristics were balanced. Participants classified specimens as non-lobular BC versus mixed BC versus ILC. Pairwise inter-observer agreement and agreement with a pre-defined reference diagnosis were determined with Cohen's kappa statistics. Subtype calls were correlated with molecular features, including CDH1/E-cadherin mutation status. Thirty-five pathologists completed both sets, providing 4,305 subtype calls. Pairwise inter-observer agreement was moderate in set A (median κ = 0.58, interquartile range [IQR] 0.48-0.66) and substantial in set B (median κ = 0.75, IQR 0.56-0.86, p < 0.001). Agreement with the reference diagnosis was substantial in set A (median κ = 0.67, IQR 0.57-0.75) and almost perfect in set B (median κ = 0.86, IQR 0.73-0.93, p < 0.001). The median frequency of CDH1/E-cadherin mutations in specimens classified as ILC was 65% in set A (IQR 56-72%) and 73% in set B (IQR 65-75%, p < 0.001). Cases with variable subtype calls included E-cadherin-positive ILCs harboring CDH1 missense mutations, and E-cadherin-negative ILCs with tubular elements and focal P-cadherin expression. ILCs with trabecular growth pattern were often misclassified as non-lobular BC in set A but not in set B. In conclusion, subtyping of BC as ILC achieves almost perfect agreement with a pre-defined reference standard, if assessment is supported by E-cadherin IHC. CDH1 missense mutations associated with preserved E-cadherin protein expression, E- to P-cadherin switching in ILC with tubular elements, and trabecular ILC were identified as potential sources of discordant classification.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Carcinoma, Lobular Type of study: Diagnostic_studies / Prognostic_studies Limits: Female / Humans Language: En Journal: J Pathol Clin Res Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Carcinoma, Lobular Type of study: Diagnostic_studies / Prognostic_studies Limits: Female / Humans Language: En Journal: J Pathol Clin Res Year: 2022 Document type: Article